[go: up one dir, main page]

MX2010008039A - Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos. - Google Patents

Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos.

Info

Publication number
MX2010008039A
MX2010008039A MX2010008039A MX2010008039A MX2010008039A MX 2010008039 A MX2010008039 A MX 2010008039A MX 2010008039 A MX2010008039 A MX 2010008039A MX 2010008039 A MX2010008039 A MX 2010008039A MX 2010008039 A MX2010008039 A MX 2010008039A
Authority
MX
Mexico
Prior art keywords
antagonistic activity
corticotropin
pharmaceutical compositions
compositions containing
releasing factor
Prior art date
Application number
MX2010008039A
Other languages
English (en)
Inventor
Takafumi Takai
Yasutaka Hoashi
Kazuyoshi Aso
Katsumi Kobayashi
Takuto Kojima
Kazuyuki Tokumaru
Michiyo Mochizuki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MX2010008039A publication Critical patent/MX2010008039A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporciona un compuesto de la fórmula (I'): en donde X es un nitrógeno o CRx, Rx es un hidrógeno, etc., R1 es un grupo de hidrocarburo opcionalmente substituido etc., R2 es un grupo de hidrocarburo opcionalmente substituido, etc., el anillo A es un anillo heterocíclico de 5- a -8-miembros etc., y cada uno de Y1,. Y2 e Y3 es un carbono opcionalmente substituido o un nitrógeno, etc.; o una sal del mismo o un profármaco del mismo, que tiene actividad antagonista del receptor CRF y proporciona también el uso del mismo.
MX2010008039A 2008-01-22 2009-01-21 Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos. MX2010008039A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US655408P 2008-01-22 2008-01-22
PCT/JP2009/051299 WO2009093747A1 (en) 2008-01-22 2009-01-21 Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
MX2010008039A true MX2010008039A (es) 2010-08-10

Family

ID=40637104

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008039A MX2010008039A (es) 2008-01-22 2009-01-21 Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos.

Country Status (26)

Country Link
US (2) US8901141B2 (es)
EP (1) EP2240485B1 (es)
JP (1) JP5431341B2 (es)
KR (1) KR20100130596A (es)
CN (1) CN101981031A (es)
AR (1) AR070218A1 (es)
AU (1) AU2009206936A1 (es)
BR (1) BRPI0907230A2 (es)
CA (1) CA2712347A1 (es)
CL (1) CL2009000116A1 (es)
CO (1) CO6230982A2 (es)
CR (1) CR11636A (es)
DO (1) DOP2010000226A (es)
EA (1) EA201070876A1 (es)
EC (1) ECSP10010414A (es)
GE (1) GEP20125637B (es)
IL (1) IL207074A0 (es)
MA (1) MA32438B1 (es)
MX (1) MX2010008039A (es)
NZ (1) NZ587215A (es)
PE (1) PE20091439A1 (es)
SG (1) SG189803A1 (es)
TW (1) TW200936591A (es)
UY (1) UY31604A1 (es)
WO (1) WO2009093747A1 (es)
ZA (1) ZA201005340B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI370820B (en) * 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
SG173639A1 (en) * 2009-02-11 2011-09-29 Sunovion Pharmaceuticals Inc Histamine h3 inverse agonists and antagonists and methods of use thereof
JP2013504581A (ja) * 2009-09-11 2013-02-07 スノヴィオン ファーマシューティカルズ インコーポレイテッド ヒスタミンｈ３インバースアゴニストおよびアンタゴニストとその使用方法
CN103857657B (zh) 2011-08-18 2016-04-20 日本新药株式会社 杂环衍生物及医药
DK2825542T3 (en) 2012-03-16 2017-01-09 Vitae Pharmaceuticals Inc LIVER-X-receptor modulators
SI2825541T1 (sl) 2012-03-16 2016-10-28 Vitae Pharmaceuticals, Inc. Modulatorji jetrnega receptorja X
WO2014165816A1 (en) 2013-04-05 2014-10-09 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
CN103435618B (zh) * 2013-08-22 2016-03-23 中国药科大学 一种合成稠杂环化合物的方法
US9771372B2 (en) 2014-05-23 2017-09-26 Active Biotech Ab Compounds useful as S100-inhibitors
CN105859630B (zh) * 2015-01-22 2019-01-18 北京大学 一种咪唑酮衍生物的合成方法及应用
US20180269407A1 (en) 2015-10-01 2018-09-20 Idemitsu Kosan Co., Ltd. Benzimidazolo[1,2-a]benzimidazole carrying triazine groups for organic light emitting diodes
EP3150604B1 (en) 2015-10-01 2021-07-14 Idemitsu Kosan Co., Ltd. Benzimidazolo[1,2-a]benzimidazole carrying benzimidazolo[1,2-a]benzimidazolylyl groups, carbazolyl groups, benzofurane groups or benzothiophene groups for organic light emitting diodes
WO2018220513A1 (en) * 2017-05-31 2018-12-06 Alembic Pharmaceuticals Limited An improved process for preparation of obeticholic acid

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS516993A (en) 1974-07-05 1976-01-20 Dainippon Pharmaceutical Co Adeninjudotaino seiho
CA2432148C (en) 2000-12-28 2011-01-18 Ono Pharmaceutical Co., Ltd. Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
WO2004113300A1 (ja) 2003-06-23 2004-12-29 Ono Pharmaceutical Co., Ltd. 新規三環性複素環化合物
EP1732541A4 (en) 2004-04-07 2008-03-05 Takeda Pharmaceutical CYCLIC COMPOUNDS
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
JP2010507664A (ja) 2006-10-25 2010-03-11 武田薬品工業株式会社 ベンズイミダゾール化合物
WO2008082003A1 (en) 2006-12-29 2008-07-10 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds having crf antagonistic activity
SI2252581T1 (sl) 2008-01-22 2012-09-28 Lilly Co Eli Antagonist kappa selektivnega opioidnega receptorja
WO2009092566A1 (en) 2008-01-22 2009-07-30 Boehringer Ingelheim International Gmbh Substituted amino-benzimidazoles, medicaments comprising said compound, their use and their method of manufacture
FR2926556B1 (fr) * 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
FR2926554B1 (fr) * 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
EP2240485B1 (en) 2014-10-15
US20090186879A1 (en) 2009-07-23
IL207074A0 (en) 2010-12-30
JP5431341B2 (ja) 2014-03-05
ZA201005340B (en) 2011-10-26
JP2011509923A (ja) 2011-03-31
TW200936591A (en) 2009-09-01
MA32438B1 (fr) 2011-07-03
SG189803A1 (en) 2013-05-31
CL2009000116A1 (es) 2010-08-27
GEP20125637B (en) 2012-09-10
CN101981031A (zh) 2011-02-23
EA201070876A1 (ru) 2011-04-29
US20100298287A1 (en) 2010-11-25
NZ587215A (en) 2012-08-31
DOP2010000226A (es) 2010-10-15
AR070218A1 (es) 2010-03-25
CA2712347A1 (en) 2009-07-30
CO6230982A2 (es) 2010-12-20
PE20091439A1 (es) 2009-10-19
KR20100130596A (ko) 2010-12-13
UY31604A1 (es) 2009-08-31
ECSP10010414A (es) 2010-09-30
CR11636A (es) 2010-11-04
EP2240485A1 (en) 2010-10-20
WO2009093747A1 (en) 2009-07-30
US8901141B2 (en) 2014-12-02
BRPI0907230A2 (pt) 2019-09-24
AU2009206936A1 (en) 2009-07-30
US8785460B2 (en) 2014-07-22

Similar Documents

Publication Publication Date Title
MX2010008039A (es) Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos.
TW201129556A (en) Novel antiplatelet agent
WO2009057784A1 (ja) 複素環化合物
MX2010001190A (es) Compuesto biciclico fusionado.
MY160443A (en) Nitrogen-containing heterocyclic compound and agricultural fungicide
PH12012501711A1 (en) [5,6] heterocyclic compound
TW200611907A (en) Fused heterocyclic compound
MX2010009372A (es) Derivado heterociclico fusionado y su uso.
GEP20146026B (en) Fused pyrimidineone compounds as trpv3 modulators
TNSN08407A1 (en) Organic compounds
GEP20125426B (en) Tricyclic compounds and their use as glucocorticoid receptor modulators
MX2009007482A (es) Agentes antiparasitarios.
TN2010000091A1 (en) Substituted pyrazole derivative
MX2009010552A (es) Antagonistas de receptor de opioide periferico y usos de los mismos.
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
MX2008013520A (es) Agonistas del receptor de adenosina a3.
WO2008146914A1 (ja) 複素環化合物
WO2008126901A1 (ja) 含窒素複素環化合物およびそれを含有する医薬組成物
MY153042A (en) Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
EP1867331A4 (en) TRIAZOLE DERIVATIVE AND USE THEREOF
MX338334B (es) Derivados de rifamicina.
ATE504592T1 (de) Trehaloseverbindung und arzneimittel mit der verbindung
TW200609218A (en) Bicyclic compounds
WO2008153027A1 (ja) ピロロキノリン誘導体およびその用途

Legal Events

Date Code Title Description
FA Abandonment or withdrawal